Erratum to “Cardiovascular Protection in People With Diabetes”

In “Cardiovascular Protection in People With Diabetes,” Canadian Journal of Diabetes 2018;42(S1):S162-S169, on page S162, the fifth Key Message should read, “The requirement for pharmacological cardiovascular protection therapies (statins, angiotensin-converting enzyme inhibitors or angiotensin-2 receptor blockers, and anti-platelets) should consider both an individual’s proximate and lifetime cardiovascular disease event risk.” Cardiovascular...